QuidelOrtho Expects Q4 Revenue of $702-707M

By Tamara Parker • Monday, January 13 10:24 • Permanent Link

QuidelOrtho Corporation (NASDAQ: QDEL) has just released its preliminary unaudited revenue for the fourth quarter ending on December 29, 2024. The company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which aligns with its previously announced 2024 financial guidance.

This revenue includes non-respiratory reported revenue in the range of approximately $561 million to $563 million and respiratory reported revenue in the range of approximately $141 million to $143 million. These figures indicate a positive end to the year for QuidelOrtho, as they expect to deliver top-line results above the mid-point of their 2024 financial guidance.

Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho, expressed optimism about the company's performance, stating, "We closed the year on a positive note and expect to deliver top-line results above the mid-point of our 2024 financial guidance."

The company is set to report its financial results for the fourth quarter and full year 2024 after the market closes on Wednesday, February 12, 2025. QuidelOrtho will also hold a conference call to discuss its financial results on the same day at 2:00 p.m. PT / 5:00 p.m. ET.

These preliminary unaudited revenues are based on management’s initial analysis and are subject to adjustments based on the company’s completion of its year-end financial close process. QuidelOrtho's dedication to advancing diagnostics to power a healthier future is evident in its continued performance in the market. The market has reacted to these announcements by moving the company's shares -4.5% to a price of $43.67. For the full picture, make sure to review QuidelOrtho's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.